Literature DB >> 11369186

Massive muscle cell degeneration in the early stage of merosin-deficient congenital muscular dystrophy.

Y K Hayashi1, Z Tezak, T Momoi, I Nonaka, C A Garcia, E P Hoffman, K Arahata.   

Abstract

Primary merosin-deficient congenital muscular dystrophy (CMD) is a severe form of congenital muscular disorder which is caused by mutations in the laminin alpha2 chain gene (LAMA2). The disease is characterized by marked dystrophic changes in skeletal muscles during early infancy, while little is known about the pathological process of the muscle fiber degeneration. Here, we report the immunohistochemical analysis of skeletal muscle in ten patients with primary merosin-deficient CMD using a panel of molecular markers for skeletal muscle proteins, cellular necrosis, and apoptosis. In the youngest patient (a 52 day old baby), prominent massive muscle cell degeneration occurred in association with the deposition of the C5-9 complement membrane attack complex (MAC). Most of the MAC-positive muscle fibers showed a severely deranged immunoreaction to dystrophin, dystroglycans, and other sarcolemmal proteins. In addition, we found scattered positive signals for apoptosis. Similar but milder changes were also observed in six other patients younger than 1 year. In the patients older than 3 years, muscle fibers positive for MAC and apoptotic signals were barely detectable. These findings imply that massive muscle fiber degeneration occurs in the very early stage of merosin-deficient CMD and may contribute to the severe dystrophic changes in muscle from early infancy.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369186     DOI: 10.1016/s0960-8966(00)00203-0

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  27 in total

Review 1.  Congenital muscular dystrophies: toward molecular therapeutic interventions.

Authors:  James Collins; Carsten G Bönnemann
Journal:  Curr Neurol Neurosci Rep       Date:  2010-03       Impact factor: 5.081

2.  Proinflammatory signals and the loss of lymphatic vessel hyaluronan receptor-1 (LYVE-1) in the early pathogenesis of laminin alpha2-deficient skeletal muscle.

Authors:  Katherine E Wardrop; Janice A Dominov
Journal:  J Histochem Cytochem       Date:  2011-02       Impact factor: 2.479

Review 3.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 4.  Laminin-211 in skeletal muscle function.

Authors:  Johan Holmberg; Madeleine Durbeej
Journal:  Cell Adh Migr       Date:  2012-11-15       Impact factor: 3.405

5.  Muscle-specific expression of insulin-like growth factor 1 improves outcome in Lama2Dy-w mice, a model for congenital muscular dystrophy type 1A.

Authors:  Ajay Kumar; Jenny Yamauchi; Tanya Girgenrath; Mahasweta Girgenrath
Journal:  Hum Mol Genet       Date:  2011-03-26       Impact factor: 6.150

Review 6.  The genetic and molecular basis of muscular dystrophy: roles of cell-matrix linkage in the pathogenesis.

Authors:  Motoi Kanagawa; Tatsushi Toda
Journal:  J Hum Genet       Date:  2006-09-13       Impact factor: 3.172

7.  Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy.

Authors:  Jachinta E Rooney; Praveen B Gurpur; Zipora Yablonka-Reuveni; Dean J Burkin
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

8.  Inhibition of apoptosis improves outcome in a model of congenital muscular dystrophy.

Authors:  Mahasweta Girgenrath; Janice A Dominov; Christine A Kostek; Jeffrey Boone Miller
Journal:  J Clin Invest       Date:  2004-12       Impact factor: 14.808

9.  Distinct roles for laminin globular domains in laminin alpha1 chain mediated rescue of murine laminin alpha2 chain deficiency.

Authors:  Kinga I Gawlik; Mikael Akerlund; Virginie Carmignac; Harri Elamaa; Madeleine Durbeej
Journal:  PLoS One       Date:  2010-07-19       Impact factor: 3.240

10.  Pathology is alleviated by doxycycline in a laminin-alpha2-null model of congenital muscular dystrophy.

Authors:  Mahasweta Girgenrath; Mary Lou Beermann; Vivek K Vishnudas; Sachiko Homma; Jeffrey Boone Miller
Journal:  Ann Neurol       Date:  2009-01       Impact factor: 10.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.